Svend A. Mortensen et al. JCHF 2014;2:

Slides:

Advertisements

Similar presentations

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Path to an Angiotensin Receptor Antagonist-Neprilysin.

Advertisements

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:

From: Assessing the Risk of Progression From Asymptomatic Left Ventricular Dysfunction to Overt Heart Failure: A Systematic Overview and Meta-Analysis.

Copyright © 2015 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved.

Copyright © 2014 American Medical Association. All rights reserved.

Stephen W. Waldo et al. JACC 2008;51:

Results of random-effects meta-analysis of association between use of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers and.

Diabetes Mellitus and Heart Failure

Clyde W. Yancy et al. JACC 2017;70:

Clyde W. Yancy et al. JACC 2017;70:

Figure 1 Energy supply–demand matching in health and heart failure

Frederic Rahbari-Oskoui, MD, MS American Journal of Kidney Diseases

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

Eugene Braunwald JCHF 2013;1:1-20

Stavros V. Konstantinides et al. JACC 2016;67:

Dean J. Kereiakes et al. JACC 2017;70:

Antoni Bayés-Genís JCHF 2015;3:

Orly Vardeny et al. JCHF 2014;2:

G. Michael Felker et al. JCHF 2014;2:

Dileep Raman et al. JACEP 2017;3:

Belinda Gray et al. JCHF 2013;1:

Mohit K. Turagam et al. JACEP 2017;3:

John A. Bittl et al. JACC 2016;68:

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

Mintu P. Turakhia et al. JACEP 2016;2:

Mitsunori Maruyama et al. JACEP 2017;3:

Jordan B. King et al. JCHF 2016;4:

Svend A. Mortensen et al. JCHF 2014;2:

Ivan C. Gerling et al. JCHF 2013;1:

Emilce Trucco et al. JACEP 2018;j.jacep

Ioannis Smyrnias et al. JACC 2019;73:

Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor.

Connie W. Tsao et al. JCHF 2016;4:

Toshiaki Toyota et al. JCIN 2017;10:27-37

Neal A. Chatterjee et al. JCHF 2014;2:

Peter E. Carson et al. JCHF 2015;3:

Mintu P. Turakhia et al. JACEP 2016;2:

Simon W. Rabkin et al. JACEP 2017;3:

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

Emilce Trucco et al. JACEP 2018;j.jacep

Evaluation of a complex intervention to improve primary care prescribing: a phase IV segmented regression interrupted time series analysis by Sean MacBride-Stewart,

Rami Doukky et al. JCHF 2016;4:24-35

Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter? Dimitris Mavridis, PhD American Journal.

Michael H. Chiu, MD, Msc, Nakul C. Sharma, MD, MPH CJC Open

Maria Rosa Costanzo et al. JCHF 2016;4:95-105

Jordan B. King et al. JCHF 2016;4:

N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels for patients undergoing surgical aortic valve replacement (SAVR) (A), patients undergoing.

Natasha A. Loghmanpour et al. JCHF 2016;4:

Davide Capodanno et al. JCIN 2009;2:

Khadijah Breathett et al. JCHF 2017;5:

Connie W. Tsao et al. JCHF 2016;4:

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Pamela E. Scott et al. JACC 2018;71:

Christian Madelaire et al. JCHF 2018;6:

(A) Distribution of CsA nephrotoxicity lesions according to antihypertensive treatment and CsA C2 levels. (A) Distribution of CsA nephrotoxicity lesions.

Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.

Zeenat Safdar et al. JCHF 2014;2:

A: Forest plot of the HR of AE of bone fracture between the saxagliptin and placebo groups across subgroups by demographic and medical history parameters.

Orly Vardeny et al. JCHF 2016;4:

An updated general approach for achieving BP goals in people with diabetes. An updated general approach for achieving BP goals in people with diabetes.

Schematic of the interaction between the renin-angiotensin-aldosterone system (RAAS) system and the natriuretic peptides and how the RAAS modulators and.

Maria R. Costanzo et al. JCHF 2016;4:

Gianluigi Savarese et al. JCHF 2016;4:

Analysis of receiver operating characteristic of three models (model 1: cardiac troponin T (cTnT), N-terminal pro brain natriuretic peptide (NT-proBNP),

Effect of methylprednisolone versus placebo on the risk of acute kidney injury: subgroup analysis by preoperative chronic kidney disease. Effect of methylprednisolone.

Changes in the plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level from baseline to treatment titration and 3 months of therapy: full analysis.

Flow diagram of the recommended pharmacological management of heart failure adapted from the European Society of Cardiology guidelines Flow diagram.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

Overall survival in all cases.

Presentation transcript:

Svend A. Mortensen et al. JCHF 2014;2:641-649 Results of Subgroup Analyses Shown are the adjusted HR for the primary endpoint within specific subgroups. The dotted line denotes HR; horizontal lines represent 95% CI. HR indicates the relative risk in the coenzyme Q10 (CoQ10) group versus the placebo group within each stratum. To convert values for NT-proBNP to picomoles per liter, divide by 8.457. ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; NT-proBNP = N-terminal pro–B-type natriuretic peptide; NYHA = New York Heart Association; other abbreviations as in Figure 1. Svend A. Mortensen et al. JCHF 2014;2:641-649 American College of Cardiology Foundation